Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Emergent BioSolutions Inc (NYSE:EBS)

32.97
Delayed Data
As of 11:07am ET
 +0.14 / +0.43%
Today’s Change
19.31
Today|||52-Week Range
34.50
+21.08%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.3B

Company Description

Emergent BioSolutions, Inc. is a biopharmaceutical company. It focuses on the research, development, and manufacture of novel vaccines and related products for prophylactic and therapeutic use against common diseases and biological weapons of mass destruction. The company operates through two segments: Biodefense and Biosciences. The Biodefense segment focuses on vaccines and antibody therapies for use against the infectious disease anthrax. The Biosciences segment focuses on protein therapies to treat certain types of cancer and vaccines for use against infectious diseases. The company was founded in May 1998 and is headquartered in Rockville, MD.

Contact Information

Emergent BioSolutions, Inc.
2273 Research Boulevard
Rockville Maryland 20850
P:(301) 795-1800
Investor Relations:
(301) 795-1877

Employees

Shareholders

Other institutional41.27%
Mutual fund holders40.63%
Individual stakeholders29.46%

Top Executives

Daniel J. Abdun-NabiPresident, Chief Executive Officer & Director
Robert G. KramerCFO, Treasurer & Executive VP-Corporate Services
W. James JacksonChief Scientific Officer & Senior Vice President
Anatolio B. CruzSecretary, Chief Compliance Officer & Executive VP
Adam R. HaveyExecutive VP & President-BioDefense Division